OBJECTIVE: To elaborate a new algorithm to establish a standardized method to define cuff-offs for CSF biomarkers of Alzheimer's disease (AD) by validating the algorithm against CSF classification derived from PET imaging. METHODS: Low and high levels of CSF phosphorylated tau were first identified to establish optimal cut-offs for CSF amyloid-β peptide (Aβ) biomarkers. These Aβ cut-offs were then used to determine cut-offs for CSF tau and phosphorylated tau markers. We compared this algorithm to a reference method, based on tau and amyloid PET imaging status (ADNI study), and then applied the algorithm to 10 large clinical cohorts of patients. RESULTS: A total of 6,922 subjects with CSF biomarkers data were included (mean (SD) age: 70.6 (8...
Introduction: We aimed to provide cut points for the automated Elecsys Alzheimer's disease (AD) cere...
Abstract Objectives: To define CSF β-amyloid 1–42 (Aβ42) cutpoints to detect cortical amyloid deposi...
Background/Aims: Disease-modifying therapy for Alzheimer’s disease (AD) has led to a need for biomar...
BACKGROUND AND OBJECTIVES: To elaborate a new algorithm to establish a standardized method to define...
INTRODUCTION: We studied whether fully automated Elecsys cerebrospinal fluid (CSF) immunoassay resul...
Introduction Changes in cerebrospinal fluid (CSF) tau and amyloid β (Aβ)42 accompany development ...
OBJECTIVE: To study cerebrospinal fluid (CSF) biomarkers of Alzheimer's disease (AD) analyzed by ful...
Background: β-amyloid (Aβ) positron emission tomography (PET) imaging is currently the only Food and...
Background: Clinical diagnosis of Alzheimer’s disease (AD) increasingly incorporates CSF biomarkers....
BACKGROUND: The Centiloid scale has been developed to standardize measurements of amyloid PET imagin...
Introduction: We studied whether fully automated Elecsys cerebrospinal fluid (CSF) immunoassay resul...
Establishing the in vivo diagnosis of Alzheimer€™s disease (AD) or other dementias relies on clinica...
abstract: Establishing the in vivo diagnosis of Alzheimer’s disease (AD) or other dementias relies o...
INTRODUCTION: Changes in cerebrospinal fluid (CSF) tau and amyloid β (Aβ)42 accompany development of...
Background Recently, biomarkers have been suggested to be incorporated into diagnostic criteria for ...
Introduction: We aimed to provide cut points for the automated Elecsys Alzheimer's disease (AD) cere...
Abstract Objectives: To define CSF β-amyloid 1–42 (Aβ42) cutpoints to detect cortical amyloid deposi...
Background/Aims: Disease-modifying therapy for Alzheimer’s disease (AD) has led to a need for biomar...
BACKGROUND AND OBJECTIVES: To elaborate a new algorithm to establish a standardized method to define...
INTRODUCTION: We studied whether fully automated Elecsys cerebrospinal fluid (CSF) immunoassay resul...
Introduction Changes in cerebrospinal fluid (CSF) tau and amyloid β (Aβ)42 accompany development ...
OBJECTIVE: To study cerebrospinal fluid (CSF) biomarkers of Alzheimer's disease (AD) analyzed by ful...
Background: β-amyloid (Aβ) positron emission tomography (PET) imaging is currently the only Food and...
Background: Clinical diagnosis of Alzheimer’s disease (AD) increasingly incorporates CSF biomarkers....
BACKGROUND: The Centiloid scale has been developed to standardize measurements of amyloid PET imagin...
Introduction: We studied whether fully automated Elecsys cerebrospinal fluid (CSF) immunoassay resul...
Establishing the in vivo diagnosis of Alzheimer€™s disease (AD) or other dementias relies on clinica...
abstract: Establishing the in vivo diagnosis of Alzheimer’s disease (AD) or other dementias relies o...
INTRODUCTION: Changes in cerebrospinal fluid (CSF) tau and amyloid β (Aβ)42 accompany development of...
Background Recently, biomarkers have been suggested to be incorporated into diagnostic criteria for ...
Introduction: We aimed to provide cut points for the automated Elecsys Alzheimer's disease (AD) cere...
Abstract Objectives: To define CSF β-amyloid 1–42 (Aβ42) cutpoints to detect cortical amyloid deposi...
Background/Aims: Disease-modifying therapy for Alzheimer’s disease (AD) has led to a need for biomar...